Business Context and Reporting Period
Company: Ocular Therapeutix, Inc. (OCUL)
Filing Type: Form 8-K (Current Report)
Date of Report: September 30, 2025
Principal Event: Entry into a Material Definitive Agreement for an underwritten public offering of common stock.
Key Financial Metrics and Offering Details
- Shares Offered: 37,909,018 shares of Common Stock.
- Offering Price: $12.53 per share.
- Underwriting Price: $11.7782 per share.
- Estimated Net Proceeds: Approximately $445.9 million (after underwriting discounts, commissions, and estimated expenses).
- Underwriters: BofA Securities, Inc., TD Securities (USA) LLC, and Piper Sandler & Co.
- Expected Closing Date: On or about October 1, 2025.
Material Changes and Liquidity Impact
This filing represents a significant capital raise event rather than a periodic financial performance report. Consequently, standard metrics such as revenue, profit, operating margins, and historical cash flow for the period are not provided in this document. The primary material change is the anticipated increase in liquidity and cash reserves resulting from the offering.
Guidance, Outlook, and Management Commentary
Cash Runway
Management estimates that the net proceeds from this offering, combined with existing cash and cash equivalents, will fund planned operating expenses, debt service obligations, and capital expenditure requirements into 2028.
Use of Proceeds and Scope
- Proceeds will support the observance of the minimum liquidity covenant of $20.0 million under the Company's existing credit and security agreement.
- Planned expenses include manufacturing scale-up and pre-commercialization activities for the product AXPAXLI.
- Limitation: The current operating plan does not include the full expenses anticipated to support the full commercialization of AXPAXLI.
Risks and Contingencies
The filing includes a cautionary note regarding forward-looking statements. Actual results may differ due to uncertainties in market conditions, the satisfaction of closing conditions, and the potential need for additional financing. The Company disclaims any obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the final closing of the offering and the actual net proceeds received versus the estimated $445.9 million.
- Review the final prospectus supplement for specific risk factors related to the offering and the commercialization of AXPAXLI.
- Monitor the Company's cash burn rate to confirm if the "into 2028" runway estimate holds, particularly given the exclusion of full commercialization costs for AXPAXLI.
- Check for any subsequent filings regarding the satisfaction of the $20.0 million minimum liquidity covenant.